---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-020227"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2023-07-19T23:59:59+00:00"
generated_at: "2026-06-13T06:23:01.741967+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex raises $7.5M gross in registered direct offering of stock and warrants

## Summary
- Offering of 7,425,744 shares plus warrants for same number at $1.01 per unit.
- Warrants exercisable at $0.885 per share, 5-year term, immediate exercisability.
- Gross proceeds expected ~$7.5M; net proceeds ~$6.7M after fees and expenses.
- Proceeds to be used for working capital and general corporate purposes.
- H.C. Wainwright acts as exclusive placement agent; offering closes July 21, 2023.

## SEC filing metadata
- accession: 0001437749-23-020227
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2023-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774923020227/0001437749-23-020227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774923020227/gnpx20230717_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-020227
- JSON: https://secwatch.observer/filing/0001437749-23-020227.json
- Plain text: https://secwatch.observer/filing/0001437749-23-020227.txt

## Key facts
- Material Agreements
  Genprex, Inc. entered into Purchase Agreement with accredited healthcare-focused institutional investors valued at approximately $6.7 million (effective 2023-07-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: accredited healthcare-focused institutional investors
  - Value: approximately $6.7 million
  - Effective: 2023-07-18
  source text: On July 18, 2023, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with accredited healthcare-focused institutional investors (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Offering”) priced at the market under Nasdaq rules, an aggregate of (i) 7,425,744 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) warrants (the “Warrants”) exercisable for up to an aggregate of 7,425,744 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774923020227/0001437749-23-020227-index.htm
- Material Agreements
  Genprex, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  source text: Pursuant to an Engagement Letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company agreed to pay the Placement Agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate gross proceeds received in the Offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds of the Offering, (iii) $50,000 for fees and expenses of the Placement Agent’s counsel and other out of pocket expenses, (iv) a non-accountable expense allowance of $25,000 and (v) $15,950 for the clearing expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774923020227/0001437749-23-020227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.